At a glance
- Originator Teijin Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Prostaglandin E1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 14 Nov 2000 Discontinued-Preclinical for Atherosclerosis in Japan (SC)
- 28 Jul 1998 No-Development-Reported for Atherosclerosis in Japan (SC)
- 28 Nov 1995 Preclinical development for Atherosclerosis in Japan (SC)